Acne Conglobata: Understanding This Rare Form of Acne and Management Strategies.

IF 4.2 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-08-23 DOI:10.1007/s13555-025-01523-x

Angela Yen Moore, Kara K Hurley

{"title":"Acne Conglobata: Understanding This Rare Form of Acne and Management Strategies.","authors":"Angela Yen Moore, Kara K Hurley","doi":"10.1007/s13555-025-01523-x","DOIUrl":null,"url":null,"abstract":"Acne conglobata is a severe, often eruptive, form of acne included in the follicular occlusion tetrad along with hidradenitis suppurativa, pilonidal cysts, and dissecting cellulitis of the scalp. The pathogenesis is complex and likely multifactorial with contribution from both extrinsic and intrinsic factors. Studies have shown a slight male predominance. Acne conglobata is clinically characterized by large, purulent nodules and abscesses, coalescing into large masses or plaques. It is often recalcitrant to common acne therapies, making management difficult for clinicians. Isotretinoin is considered the first-line therapy but must be started at a conservative dosage as it can paradoxically worsen flares. Biologic agents, such as tumor necrosis factor (TNF) and interleukin (IL)-17 inhibitors, along with photodynamic therapy (PDT) and carbon dioxide (CO2) laser therapy have been reported as effective. Large prospective studies focusing on the management of acne conglobata are lacking. Acne conglobata often causes severe scarring, creating a large psychosocial burden for the patient and negatively impacting quality of life.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01523-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acne conglobata is a severe, often eruptive, form of acne included in the follicular occlusion tetrad along with hidradenitis suppurativa, pilonidal cysts, and dissecting cellulitis of the scalp. The pathogenesis is complex and likely multifactorial with contribution from both extrinsic and intrinsic factors. Studies have shown a slight male predominance. Acne conglobata is clinically characterized by large, purulent nodules and abscesses, coalescing into large masses or plaques. It is often recalcitrant to common acne therapies, making management difficult for clinicians. Isotretinoin is considered the first-line therapy but must be started at a conservative dosage as it can paradoxically worsen flares. Biologic agents, such as tumor necrosis factor (TNF) and interleukin (IL)-17 inhibitors, along with photodynamic therapy (PDT) and carbon dioxide (CO₂) laser therapy have been reported as effective. Large prospective studies focusing on the management of acne conglobata are lacking. Acne conglobata often causes severe scarring, creating a large psychosocial burden for the patient and negatively impacting quality of life.

查看原文本刊更多论文

综合痤疮：了解这种罕见形式的痤疮和管理策略。

综合痤疮是一种严重的、经常爆发的痤疮，包括在毛囊闭塞四分体中，同时伴有化脓性汗腺炎、毛囊囊肿和头皮剥离蜂窝织炎。发病机制复杂，可能是多因素的，既有外在因素，也有内在因素。研究显示男性有轻微的优势。多发性痤疮的临床特征是大的化脓性结节和脓肿，合并成大块或斑块。它通常对常见的痤疮治疗是顽固的，使临床医生难以管理。异维a酸被认为是一线治疗，但必须以保守剂量开始，因为它可能会加剧耀斑。生物制剂，如肿瘤坏死因子（TNF）和白细胞介素(IL)-17抑制剂，以及光动力治疗（PDT）和二氧化碳（CO2）激光治疗已被报道为有效。大型前瞻性研究集中于管理的痤疮整体性缺乏。多发性痤疮通常会造成严重的疤痕，给患者造成巨大的心理负担，并对生活质量产生负面影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.